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Abstract
Innate immune signaling via TLR4 plays critical roles in pathogene-
sis of metabolic disorders, but the contribution of different lipid
species to metabolic disorders and inflammatory diseases is less
clear. GM3 ganglioside in human serum is composed of a variety of
fatty acids, including long-chain (LCFA) and very-long-chain
(VLCFA). Analysis of circulating levels of human serum GM3 species
from patients at different stages of insulin resistance and chronic
inflammation reveals that levels of VLCFA-GM3 increase signifi-
cantly in metabolic disorders, while LCFA-GM3 serum levels
decrease. Specific GM3 species also correlates with disease symp-
toms. VLCFA-GM3 levels increase in the adipose tissue of obese
mice, and this is blocked in TLR4-mutant mice. In cultured mono-
cytes, GM3 by itself has no effect on TLR4 activation; however,
VLCFA-GM3 synergistically and selectively enhances TLR4 activa-
tion by LPS/HMGB1, while LCFA-GM3 and unsaturated VLCFA-GM3
suppresses TLR4 activation. GM3 interacts with the extracellular
region of TLR4/MD2 complex to modulate dimerization/oligomer-
ization. Ligand-molecular docking analysis supports that VLCFA-
GM3 and LCFA-GM3 act as agonist and antagonist of TLR4 activity,
respectively, by differentially binding to the hydrophobic pocket of
MD2. Our findings suggest that VLCFA-GM3 is a risk factor for
TLR4-mediated disease progression.
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Introduction
Chronic inflammation plays critical roles in pathogenesis of a variety
of human diseases, including metabolic disorders (Lumeng, 2011;
Hotamisligil, 2017). Prolonged and abnormal activation of pattern
recognition receptors in innate immune system, such as Toll-like
receptors (TLR; Kawai & Akira, 2011; Moresco et al, 2011), causes
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chronic inflammation. In metabolic disorders, various ligands activate
TLR4: (i) exogenous lipopolysaccharides elevated in serum (Cani
et al, 2007), (ii) endogenous damage-associated molecular patterns
(DAMPs), e.g., high-mobility group box-1 protein (HMGB1; Harris
et al, 2012; Guzma´n-Ruiz et al, 2014), free fatty acids (FFAs; Shi et al,
2006), and fetuin-A protein (Pal et al, 2012), which are released from
macrophages and adipose tissue. LPS and endogenous ligands induce
production of various effector molecules including proinflammatory
cytokines (e.g., tumor necrosis factor-a [TNF-a], interleukin-6 [IL-6]),
which contributes to insulin resistance and dysregulation of lipid and
energy metabolisms (Lumeng, 2011; Hotamisligil, 2017).
Gangliosides are important downstream metabolites of ceramide,
a sphingolipid formed by an amide linkage between the sphingoid
base and fatty acid (Bikman & Summers, 2011), and involved in a
variety of cellular events (Inokuchi et al, 2018). Glycosyltrans-
ferases, UGCG and B4GALT5/6, convert ceramide into glucosylce-
ramide (GlcCer) and lactosylceramide (LacCer), precursor
glycosphingolipids (GSLs) for GM3 ganglioside. Consecutively,
ST3GAL5, a GM3 synthase (GM3S), converts LacCer into GM3 by
conjugating a sialic acid (N-acetylneuraminic acid) (Fig 1A), which
is followed by biosynthesis of complex gangliosides.
GM3 is secreted abundantly into human serum (Fig 1B), with
concentration 10–15 lg/ml (~10 lM) (Fig 1C), and is circulated to
all parts of the body, including insulin-sensitive organs (e.g., liver,
muscle, adipose; Senn et al, 1989; Veillon et al, 2015). Fatty acids
of serum GM3 are composed of long-chain fatty acid (LCFA), 16:0,
18:0, and 20:0; very-long-chain fatty acid (VLCFA), 22:0, 23:0, and
24:0; unsaturated VLCFA, 22:1 and 24:1; and a-hydroxy VLCFA
including h24:0 and h24:1 (Fig 1D), in almost same abundances of
LCFA, VLCFA, and unsaturated VLCFA species, and a small amount
of a-hydroxy species (Fig 1E). Altered expression of various GM3
species has been observed in patients with metabolic disorders
(Veillon et al, 2015); however, specific biological functions of these
species are poorly understood.
On the other hand, it has been suggested that GM3 on the plasma
membrane plays important roles in pathogenesis of metabolic disor-
ders (Inokuchi et al, 2018). GM3 is also a major ganglioside in
adipocytes, and its expression is induced by proinflammatory
cytokines derived from adipose tissue macrophages (Tagami et al,
2002; Nagafuku et al, 2015; Wentworth et al, 2016). GM3 biosyn-
thesis occurs in Golgi, and it subsequently becomes secreted into
extracellular compartment or localized in plasma membrane as a
component of membrane microdomains (also called “rafts”), which
are signaling platforms comprised of sphingolipids (Lingwood &
Simons, 2010). GM3 on plasma membrane affects diffusion kinetics
of insulin receptors and regulates signal transduction (Kabayama
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Figure 1. Molecular species of ganglioside GM3 in human serum and the acyl-chain structures.
A Biosynthetic pathway (schematic) of GM3, from ceramide, and to complex gangliosides.
B TLC analysis of ganglioside species in human serum.
C Quantification by densitometry of major ganglioside species GM3 and GD1a in human serum. Data expressed as mean  SD, n = 6.
D Detailed structures of GM3 species: sialyllactose head group, sphingoid base (d18:1), typical fatty-acid lengths (LCFA, VLCFA), and acyl-chain modifications
(a-hydroxylation, x-9 desaturation).
E Quantification by LC-MS/MS analysis of serum GM3 species with differing acyl-chain structures. Total abundance of 10 species was defined as 1. Data expressed as
mean  SD, n = 6.
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et al, 2007); conversely, insulin signaling is restored when GM3
biosynthesis is blocked by glycosyltransferase inhibitors, e.g., D-
threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-
PDMP) and Genz-123346 (Tagami et al, 2002; Zhao et al, 2007).
Knockout of GM3S diminishes not only systemic insulin resistance
but also chronic inflammation in adipose tissue (Yamashita et al,
2003; Nagafuku et al, 2015), suggesting that GM3 might be involved
in innate immune signaling upstream of insulin resistance; however,
the molecular basis for such relationship remains unclear.
In this study, we investigated how serum GM3 species, carrying
different acyl chains, regulate inflammatory signaling and contribute
to onset of metabolic disorders. Here, we demonstrate that GM3 acts
as an endogenous TLR4 modulator. VLCFA-GM3 synergistically and
selectively augmented TLR4 activation by LPS and HMGB1, and in
contrast, LCFA and unsaturated VLCFA-GM3 suppressed TLR4 acti-
vation. Serum VLCFA-GM3 increased significantly and LCFA-GM3
decreased sharply in metabolic disorders. Computational
approaches using artificial intelligence revealed that specific GM3
species are related to clinical symptoms. VLCFA-GM3 also increased
in the adipose tissue of obese mice and the increase was attenuated
in TLR4-mutant mice, implying that TLR4 signaling itself is involved
in production of VLCFA-GM3. Our findings suggest that serum GM3
plays a role of rheostat for TLR4 signaling, and the increase in
VLCFA-GM3 is a risk factor for TLR4-mediated disease progression.
Results
VLCFA-GM3 species are involved in progression of chronic
inflammation in metabolic disorders
To elucidate the role of GM3 species in pathophysiology of meta-
bolic disorders, we analyzed expression patterns of serum GM3
species in human subjects (Veillon et al, 2015; Appendix Fig S1A–
I). Sera were collected from human subjects, representing five
pathological phases: healthy subjects (control, n = 24), visceral fat
accumulation (VFA, n = 38) in presymptomatic phase, VFA with
dyslipidemia (lipidemia, n = 28), VFA with hyperglycemia
(glycemia, n = 15), and VFA with dyslipidemia and hyperglycemia
(lipidemia + glycemia, n = 17). Scores of homeostatic model assess-
ment for insulin resistance (HOMA-IR) and serum C-reactive protein
(CRP) were evaluated as indicators of insulin resistance and chronic
inflammation, respectively. HOMA-IR and CRP displayed significant
correlation with each other (Appendix Fig S1J), and a gradual
increase in the order: control < VFA < lipidemia < glycemia < lipi-
demia + glycemia (Appendix Fig S1K and L). These findings indi-
cate that the order of the five phases corresponds to increasing
severity of insulin resistance and chronic inflammation.
Circulating levels of serum GM3 species were evaluated by LC-
MS/MS analysis (Appendix Fig S2A–K). Heat map analysis, which
summarizes properties of the ten major species, indicated progres-
sive increase in VLCFA species and decrease in LCFA species in
association with increases in HOMA-IR and serum CRP (Fig 2A).
LCFA species (16:0, 18:0, 20:0) decreased sharply in VFA, lipidemia,
and glycemia (Fig 2B), whereas VLCFA species (22:0, 23:0, 24:0,
h24:0) largely increased (Fig 2C). Unsaturated VLCFA species were
mostly constant as total (Fig 2D); 22:1 and h24:1 decreased, but
24:1 slightly increased (Fig 2A). The ratio of total VLCFA species to
total LCFA/ unsaturated VLCFA species increased notably in
presymptomatic and early phases of metabolic disorders
(Appendix Fig S2L).
Early-phase increases in body mass index (BMI) (> 25) or
abdominal circumference (> 85 cm) were associated with sharp
reduction in LCFA species (Figs 2E and EV1A) and increase in
VLCFA species (Figs 2F and EV1B). These findings suggest that
increases in VLCFA-GM3 species occur in obesity, and play a role in
early pathogenesis of metabolic disorders. In cases of severe obesity
(BMI > 30 and/or abdominal circumference > 100 cm) and severe
metabolic disorders (lipidemia + glycemia), there was moderate
reduction in VLCFA-GM3 species (Figs 2F and EV1B) and significant
increase in unsaturated species (Figs 2G and EV1C). These findings
indicate that desaturation of VLCFA species occurs after onset of
metabolic disorders.
Abundance of a-hydroxy VLCFA-GM3 (h24:0) showed a linear
increase along with increases in BMI and abdominal circumference
(Figs 2H and EV1D), with strong correlation (Fig EV1E and F). a-
hydroxy VLCFA-GM3 was also strongly correlated with indicators
of insulin resistance and chronic inflammation (ALT, HOMA-IR,
CRP) (Figs 2I and J, and EV1G–J). In particular, the ratio of h24:0
to 24:0 was much higher in subjects with abnormal CRP value
(> 0.3 mg/dl) (Figs 2K and EV1I), indicating considerable involve-
ment of h24:0 in chronic inflammation. Relationships between
these GM3 species and pathophysiology of metabolic disorders are
summarized schematically in Fig 2L. In steady state, homeostasis
is maintained by balance of GM3 species; in presymptomatic and
early phases, VLCFA species increase in correlation with chronic
inflammation and insulin resistance; in late phases, modifications
such as desaturation and a-hydroxylation could occur in VLCFA
species.
Artificial intelligence-based approaches revealed GM3 species
specific to disease symptoms
To analyze more detailed relationships between GM3 species and
metabolic disorders, we utilized an unbiased approach using self-
organization map (SOM), a neural-network-type artificial intelli-
gence model. Subjects were analyzed based on expression
patterns of the ten major GM3 species, then mapped onto a two-
dimensional (2D) surface such that subjects with similar GM3
patterns are located near each other and form clusters (Fig 3A).
SOM analysis gave nearly distinct clusters of control and lipidemia
subjects (Fig 3B), indicating increases in VLCFA species and
decreases in LCFA/ unsaturated VLCFA species in lipidemia
subjects (Fig 3C). These subjects were further mapped into six
sub-clusters based on expression patterns of GM3 species: in
control, sub-clusters 1 (16:0), 2 (16:0, 18:0, 20:0), and 3 (22:1,
24:1, h24:1); in lipidemia, sub-clusters 4 (22:0), 5 (22:0, 24:0,
h24:0, 23:0), and 6 (22:0, 24:0, h24:0, 24:1) (Fig 3D). This classifi-
cation indicates that elongation, a-hydroxylation, and desaturation
of GM3 acyl chains occur corresponding to disease progression
(Fig 3E). Sub-clusters 4 and 5 (higher in a-hydroxy VLCFA)
showed higher non-HDL cholesterol; sub-cluster 6 (higher in
unsaturated VLCFA) showed higher CRP and HOMA-IR (Fig 3F),
indicating fatty-acid modifications specific to different disease
severities. Optimized SOM analysis, based on four species (16:0,
18:0, 22:0, and 22:1), was able to completely distinguish control
ª 2020 The Authors The EMBO Journal 39: e101732 | 2020 3 of 20
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vs. lipidemia subjects (Fig 3G). The receiver operating characteris-
tic (ROC) curve gave excellent scores in sensitivity, specificity,
and area under the curve (AUC; Fig 3H). These findings suggest
that alterations of serum GM3 species are potential risks of
disease progression, and the measurement is a valuable tool for
clinical assessment.
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Figure 2. Alterations of relative abundance of GM3 species are involved in disease progression and chronic inflammation.
A Heat map analysis of serum GM3 species in various pathological phases: control (n = 24), VFA (n = 38), lipidemia (n = 28), glycemia (n = 15), and
lipidemia + glycemia (n = 17). Colors indicate fold change average of each species relative to control (defined as 1), as shown in key at right. Order of pathological
phases corresponds to increments of HOMA-IR and serum CRP.
B–D Properties of various GM3 species as a function of pathological phases: control (n = 24), VFA (n = 38), lipidemia (n = 28), glycemia (n = 15), and
lipidemia + glycemia (n = 17). Data shown are relative abundances of total LCFA species (16:0, 18:0, 20:0) (B), total VLCFA species (22:0, 23:0, 24:0, h24:0) (C), and
total unsaturated VLCFA species (22:1, 24:1, h24:1) (D) relative to total of ten major GM3 species (defined as 1) in each subject.
E–H Properties of various GM3 species as a function of BMI: LCFA-GM3 (E), VLCFA-GM3 (F), unsaturated VLCFA-GM3 (G), and a-hydroxy VLCFA-GM3 (h24:0) (H). Colors
indicate disease severity: light blue, no abnormal scores (n = 25); orange, early-phase obesity (n = 74); purple, severe obesity (n = 23).
I, J Spearman’s correlations for GM3 h24:0 vs. ALT (I) and vs. HOMA-IR (J).
K Plots of a-hydroxylation rate (h24:0/24:0) vs. serum CRP. Colors indicate range of CRP value (mg/dl): light blue, 0.01–0.02 (n = 21); orange, 0.03–0.09 (n = 56); gray,
0.10–0.29 (n = 29); red, 0.3–1.0 (diagnostically abnormal; n = 15).
L Association between serum GM3 species and progression of metabolic disorders (schematic).
Data information: Data shown are individual values and mean  SD, analyzed by two-tailed unpaired t-test with Bonferroni’s correction. *P < 0.05, **P < 0.01, and
***P < 0.001 for comparisons between indicated groups.
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Serum GM3 species positively and negatively regulate innate
immune responses in an acyl-chain-dependent manner
We investigated the effects of GM3 species (16:0, 18:0, 20:0, 22:0,
24:0, h24:0, and 24:1, in Fig 1D) on LPS-mediated activation of
human peripheral blood monocytes (Fig 4A). Every GM3 species by
themselves did not exhibit notable effects, but VLCFA species (22:0,
24:0) and a-hydroxy VLCFA species (h24:0) synergistically
enhanced LPS-mediated production of proinflammatory cytokines,
e.g., IL-6, TNF-a, and IL-12/23 p40 (Figs 4B and C, and EV2A). In
contrast, LCFA species (16:0, 18:0) strongly inhibited LPS-mediated
cytokine production. Unsaturated VLCFA-GM3 24:1 had an inhibi-
tory effect. These enhancing and inhibitory effects were dose-depen-
dent and were observed at physiological concentration (< 10 lM)
(Fig EV2B). These findings suggest that serum GM3 species posi-
tively and negatively regulate LPS-mediated monocyte activation in
an acyl-chain-dependent manner.
Among various types of gangliosides, only VLCFA-GM3 species
displayed dose-dependent synergistic activation (Fig 4D and E), and
other complex gangliosides exhibited inhibitory effects as reported
(Shen et al, 2008). Monocyte activation was moderately enhanced
in the presence of precursor GSL species and reached to the maxi-
mum in the presence of GM3 24:0 (Figs 4F and EV2C–E). GM3
species showed both positive and negative regulations in an acyl-
chain structure-dependent manner, but Cer, GlcCer, and LacCer did
not show such effects (Figs 4F and EV2C–E). Increasing doses of
GM3 16:0, 18:0, and 24:1 reversed the effect of GM3 22:0 and 24:0
(Figs 4G and EV2F and G), suggesting that activation of human
monocytes is regulated by the balance of LCFA-GM3, VLCFA-GM3,
and unsaturated VLCFA-GM3 species in serum.
VLCFA-GM3 species selectively enhance human TLR4/MD-2
activation
To elucidate the molecular mechanisms underlying GM3-mediated
monocyte activation, we screened signaling pathways targeted by
GM3 species. Monocytes were co-stimulated by GM3 species in
combination with various PAMPs, including ligands for TLR1/2,
TLR4, TLR5, TLR2/6, and TLR7/8. We found that VLCFA species
selectively synergized with LPS, a TLR4 ligand, but not for other TLR
ligands (Figs 5A and EV3A). LCFA species strongly inhibited cyto-
kine production by LPS, and partially by Pam3CSK4, a TLR1/2
ligand, but not by MALP-2, a TLR2/6 ligand. Thus, GM3 species act
as endogenous modulators selective for TLR4 signaling. GM3-
mediated modulations were also observed in di-/monophosphoryl
lipid A species LA506, LA505, and LA504, core structural compo-
nents of LPS (Fig 5B). VLCFA-GM3 22:0 significantly enhanced cyto-
kine production in the presence of low-dose LA506 (Fig EV3B–D).
Moreover, VLCFA species strongly enhanced cytokine production by
high-mobility group box-1 (HMGB1) protein (Fig 5C and D), an
endogenous TLR2/4 ligand released from dead cells or visceral
adipocytes in obese patients (Harris et al, 2012; Guzma´n-Ruiz et al,
2014). HMGB1-mediated IL-6 production was also inhibited by LCFA
species (Fig 5C). These findings, taken together, indicate that GM3
species selectively modulate TLR4-mediated cytokine production.
To confirm human TLR4 (hTLR4) as a target molecule of GM3
species, we reconstituted TLR4 signaling pathway in HEK293T cells.
NF-jB activity was not increased by LPS or GM3 22:0 in hTLR4
single-expressing cells; however, synergistic enhancement was
clearly observed in hTLR4/hMD-2 co-expressing cells (Fig 5E).
Neither GM3-mediated enhancement nor LPS-mediated activation
was observed in cells co-expressing dominant-negative hTLR4 vari-
ant (P714H, in intracellular domain)/hMD-2 (Fig 5E). These find-
ings suggest that hTLR4/hMD-2 complex and its downstream
pathway are required for NF-jB activation by GM3 species. Activa-
tion of hTLR4/hMD-2 by LPS was strongly enhanced by GM3 22:0,
24:0, and h24:0, but inhibited by GM3 16:0 (Fig 5F). hTLR4/hMD-2
activation enhanced by addition of recombinant soluble hCD14 was
strongly suppressed by 16:0 and 18:0 (Fig 5G), consistent with
observed inhibition of CD14-positive human cells by long-chain
species. Among the downstream targets of TLR4, in addition to
NF-jB, the activator protein 1 (AP-1) activity was moderately
enhanced by GM3 22:0, but the interferon-stimulated response
element (ISRE) activity was enhanced only weakly (Fig EV3E).
None of the GM3 species affected NF-jB activation by overexpres-
sion of MyD88-adaptor-like (Mal), a proximal adaptor protein of
hTLR4 (Fig 5H), indicating that GM3 species target hTLR4/hMD-2
complex upstream of Mal. The result of co-stimulation by LPS plus
GM3 species in 1:1 mixture suggests that the balance of extracellular
GM3 species controls activation patterns of hTLR4/hMD-2 (Fig 5I
and J). 16:0 consistently inhibited TLR4 activation even in the pres-
ence of 22:0 or 24:0; 18:0 and 20:0 substantially counteracted
enhancement by 22:0 or 24:0; and 24:1 reduced TLR4 activation to
basal level by LPS single stimulation (Fig 5I). These findings, taken
together, indicate that TLR4 signaling is selectively modulated by
balance of GM3 species (Fig 5J).
◀ Figure 3. Self-organization map (SOM) analysis based on relative abundances of serum GM3 species.A Procedure (schematic) for self-organization map (SOM) analysis, a pattern recognition method using neural-network-type artificial intelligence. Complex patterns of
multi-dimensional information (in this case, expression patterns of the ten major GM3 species in human subjects) are mapped onto a 2D surface. Subjects having
similar GM3 patterns are located proximal to each other and form several clusters (red arrows), whereas subjects having different GM3 patterns are located distal to
each other (blue arrows).
B SOM analysis of control and lipidemia subjects based on expression patterns of ten GM3 species.
C Mapping of expression levels of ten GM3 species onto SOM in (B).
D Identification of sub-clusters having different GM3 patterns based on SOM in (B).
E Metabolic pathways for fatty acids: elongation, desaturation, and a-hydroxylation (a-oxidation) (schematic). Sub-clusters identified by SOM analysis are mapped on
metabolic pathways.
F Heat map analysis for GM3 species and clinical markers of six clusters. Sample sizes: sub-clusters 1–3 (total), n = 22; cluster 4, n = 7; cluster 5, n = 9; cluster 6,
n = 12.
G Self-organization map (SOM) based on four GM3 species as indicated at bottom.
H ROC curve derived from Bayesian regularized neural networks (BRNNs) based on four GM3 species in (G).
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VLCFA-GM3 species selectively enhance mouse TLR4/MD-2
signaling
We also investigated the effects of GM3 species on mouse TLR4/
MD-2 (mTLR4/mMD-2). In RAW macrophages, VLCFA species
strongly enhanced TNF-a production by TLR4 ligands LPS and
HMGB-1 but not by other TLR ligands, similarly to results in human
cells (Fig 6A and B). The enhancement was clearly observed in
chronic/weak TLR4 activation by low-dose LPS and was saturated
in rapid/strong activation by high-dose LPS (Fig 6B). LCFA-GM3
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and unsaturated VLCFA-GM3 species moderately enhanced TLR4
activation (Fig 6A), in contrast to results in human cells. These
effects were also observed in BMDMs from C3H/HeN (WT TLR4)
mice, but not in C3H/HeJ (dominant-negative TLR4, P712H) mice
(Fig 6B), indicating that mTLR4 and its downstream signaling path-
way are required. Activation patterns of macrophages were
0 
2 
4 
6 
8 
10 
12 
R
el
at
iv
e 
Lu
c 
 A
ct
iv
ity
 
(N
F-
B
)
0 
10 
20 
30 
40 
50 
GM3 
(5 M)
LPS
16
:0
24
:0
22
:0
18
:0
20
:0
24
:1
h2
4:
0-
-
16
:0
24
:0
22
:0
18
:0
20
:0
24
:1
h2
4:
0-
+
R
el
at
iv
e 
Lu
c 
 A
ct
iv
ity
 
(N
F-
B
)
**
**
**
**
**
**
hTLR4/hMD-2 
+ soluble hCD14
A
I
B C
**
** **
**
** **
**
E
G
F
0  
2  
4  
6  
8  
10  
GM3 
(5 M)
LPS
16
:0
24
:0
22
:0
18
:0
20
:0
24
:1
h2
4:
0-
-
16
:0
24
:0
22
:0
18
:0
20
:0
24
:1
h2
4:
0-
+
R
el
at
iv
e 
Lu
c 
 A
ct
iv
ity
 
(N
F-
B
)
**
**
**
** **
hTLR4/hMD-2
0 
50 
100 
150 
200 
24
:0
22
:0
24
:1
h2
4:
0
16
:0
18
:0
20
:0-
++ (0.5 ng)
24
:0
22
:0
24
:1
h2
4:
0
16
:0
18
:0
20
:0-
+ (0.1 ng)-
-GM3 
(7.5 M)
Mal (DNA)
R
el
at
iv
e 
Lu
c 
 A
ct
iv
ity
 
(N
F-
B
)
22
:0
24
:0
 +
 2
2:
0
16
:0
 +
 2
2:
0
18
:0
 +
 2
2:
0
24
:1
 +
 2
2:
0
h2
4:
0 
+ 
22
:0-
+
GM3 mix 
(10 M)
LPS
20
:0
 +
 2
2:
0
24
:0
22
:0
 +
 2
4:
0
16
:0
 +
 2
4:
0
18
:0
 +
 2
4:
0
24
:1
 +
 2
4:
0
h2
4:
0 
+ 
24
:0
20
:0
 +
 2
4:
0
++
-
-
0 
5 
10 
15 
20 
25 
R
el
at
iv
e 
Lu
c 
 A
ct
iv
ity
 
(N
F-
B
)
**
**
**
**
**
**
**
**
hTLR4/hMD-2
H
J
TLR4 ligands 
CD14
hTLR4/MD 2
22:0 
24:0 
h24:0
16:0 
18:0 
20:0 
24:1
GM3 (VLCFA/ 
-OH VLCFA) 
TLR4/MD-2 
(WT)
TLR4/MD-2 
(P714H)
TLR4 
(WT)
 GM3 22:0 
 (5 M)
LPS - +
- -
-
+
+
+
- +
- -
-
+
+
+
- +
- -
-
+
+
+
Transfection 
4
0
5
3
2
1h
IL
-6
 (n
g/
m
L)
GM3 
(5 M)
-
-Lipid-A
- 24
:0
24
:1
16
:0
LA506
- 24
:0
24
:1
16
:0
LA505
- 24
:0
24
:1
16
:0
LA504
GM3 
(5 M)
HMGB1
16
:0
24
:0
22
:0
18
:0
20
:0
24
:1
h2
4:
0-
+
-
-
GM3 
(5 M)
HMGB1
16
:0
24
:0
22
:0
18
:0
20
:0
24
:1
h2
4:
0-
+
-
-
800
0
1,200
600
400
200
1,000
4
0
6
3
2
1
5
hI
L-
6 
(n
g/
m
L)
hT
N
F-
 (p
g/
m
L)
D
*
PAMPs 
(LPS)
DAMPs 
(HMGB1)
** ** **
**
** **
**
** **
Other TLRs
Inflammatory signaling
Mal
GM3 (LCFA/ 
-9 VLCFA)
In
du
ct
io
n 
le
ve
l 
Min 
Max 
Control 
Pam3CSK4 (TLR1/2)
LPS (TLR4)
Flagellin (TLR5)
MALP-2 (TLR2/6)
R848 (TLR7/8)
GM3 species
16:0 18:0 20:0 22:0 24:0 h24:0 24:1-
TL
R
 li
ga
nd
s
hI
L-
6 
pr
od
uc
tio
n 
Synergy
Inhibition
Figure 5.
8 of 20 The EMBO Journal 39: e101732 | 2020 ª 2020 The Authors
The EMBO Journal Hirotaka Kanoh et al
reproduced by overexpression of mTLR4/mMD-2 complex in
HEK293T cells (Fig 6C), and NF-jB activity increased progressively
associating with acyl-chain length of GM3 species. Addition of
soluble mouse CD14 enhanced the synergistic activation by GM3
species, indicating that CD14 facilitate GM3 representation to
mTLR4/mMD-2. Among complex gangliosides and precursor GSLs,
synergistic activation in the mouse model was highest for VLCFA-
GM3 species (Fig 6D and E), similarly to findings in human cells.
LCFA-GM3 (16:0, 18:0) induced synergistic activation at physiologi-
cal concentration to a similar degree as other GM3 species, but they
displayed antagonistic effects at higher concentrations (Fig 6D).
Molecular characteristics of GM3 species and effects on TLR4/MD-2
are summarized in Fig 6F and Appendix Fig S3. VLCFA-GM3 and
LCFA-GM3 displayed enhancement and inhibition for TLR4/MD-2,
respectively, correlating with volume of the hydrophobic moiety.
Interestingly, lipid A/IVa is known to show agonistic and antagonis-
tic activities correlating with total number of fatty acids, also corre-
sponding to volume of the hydrophobic moiety (Akashi et al, 2001;
Saitoh et al, 2004). Lipid IVa synergizes with LPS or lipid A in low-
dose range, but show antagonistic effects in high-dose range
(Mueller et al, 2004), similarly to LCFA-GM3. These current and
reported findings suggest that GM3 species utilize molecular mecha-
nisms closely similar to lipid A/ IVa in regulating TLR4 activation.
VLCFA-GM3 species increase in mouse adipose tissue in
metabolic disorders
In view of significant increase in VLCFA-GM3 in early-phase meta-
bolic disorders in humans, we performed comparative studies using
mouse models of obesity. Six-week-old ob/ob mice, showing early
onset of metabolic disorders (Fig EV4A), had an increased abun-
dance of GM3 in visceral adipose tissue (Fig EV4B). We analyzed
these GM3 species by LC-MS/MS. Control C57/BL6 mice had 16:0,
18:0, 20:0, 22:0, 23:0, 24:0, and 24:1 as major GM3 species, and a
small amount of a-hydroxy species (Fig 7A), showing similar
composition to human serum GM3. On the other hand, ob/ob mice
had notably increased levels of a-hydroxy GM3: a strong increase in
VLCFA species (h22:0, h23:0, h24:0), and moderate increase in
LCFA and unsaturated VLCFA species (h16:0, h18:0, h20:0, h24:1).
These findings suggest that increases in VLCFA-GM3 and a-hydroxy-
lation occur in visceral adipose tissue in obesity and metabolic
disorders.
Next, we analyzed diet-induced obese mice as a more chronic
and moderate model than ob/ob mice. High-fat diet (HFD) in 8-
week-old mice for 10 weeks resulted in obesity and increased GM3
levels (Fig EV4C and D). LC-MS/MS analysis showed increase in a-
hydroxy GM3 species in HFD (Fig 7B); however, the predominant
GM3 species in HFD mice were those with shorter acyl chains
(h18:0, h20:0, h22:0) relative to ob/ob mice (h22:0, h23:0, h24:0).
These findings indicate a correlation between the fatty-acid length
of a-hydroxy GM3 and the severity of metabolic disorders.
We previously reported that proinflammatory cytokines released
from adipose tissue-resident macrophages induce GM3 production
in adipocytes (Nagafuku et al, 2015). TLR4 is a key receptor for
cytokine productions in adipose tissue (Shi et al, 2006; Suganami
et al, 2017), implying that TLR4 activation itself induces increase in
VLCFA-GM3. So, we analyzed GM3 species in HFD C3H/HeN and
C3H/HeJ mice by LC-MS/MS. HFD in 8-week-old C3H/HeN mice for
8 weeks resulted in increased body weight, blood glucose level, and
visceral adipose tissue weight (Fig EV4E). TLC analysis showed
moderate increase in total GM3 (Figs 7C and EV4F), and LC-MS/MS
analysis revealed notable increases in a-hydroxy VLCFA-GM3
species in visceral adipose tissues of HFD C3H/HeN mice (Fig 7D).
Diabetic phenotypes and increased levels of a-hydroxy VLCFA-GM3
species were ameliorated in HFD C3H/HeJ mice (Figs 7D and
EV4E), suggesting that TLR4 signaling is partially involved in
production of a-hydroxy VLCFA species in obesity. These findings,
taken together, suggest that a-hydroxy VLCFA-GM3 increases in
both human serum and mouse adipose tissue (Fig 7E), and an inter-
play between TLR4 and GM3 species results in a feedback loop from
TLR4 to GM3 (shown schematically in Fig 7F).
GM3 species recognition by TLR4/MD-2 induces receptor
dimerization/ oligomerization
To elucidate the molecular basis of GM3 recognition and signal
transduction, we performed structure-based mutation mapping on
TLR4/MD-2 complex. Previously reported crystal structures of
TLR4/MD-2 complex (Park et al, 2009; Ohto et al, 2012a) indicate
that two ligand-binding sites are formed on the dimerization inter-
face between two TLR4/MD-2 units (Fig 8A). MD-2 forms
hydrophobic pockets that bind to the acyl-chain moiety of LPS,
while TLR4 leucine-rich repeats (LRRs) provide charged amino acids
that recognize the hydrophilic head group of LPS (Fig 8B). Lys (K)
and Arg (R) residues around the LPS-binding pocket were replaced
by Ala (A), because these cationic residues may recognize the sialic
acid on GM3 saccharide chain. Mutations of R264, K341, and K362
greatly reduced synergistic hTLR4 activation by GM3 22:0 and
◀ Figure 5. VLCFA-GM3 species synergistically and selectively control human TLR4/MD-2 activation.A Co-stimulation of human monocytes by GM3 species plus various TLR ligands: LPS (0.13 ng/ml), TLR4/MD-2, Pam3CSK4 (0.5 lg/ml), TLR1/2, Flagellin (50 ng/ml),
TLR5, R848 (0.5 lg/ml), TLR7/8, MALP-2 (1.0 ng/ml), and TLR2/6. IL-6 production in culture supernatant was quantified by ELISA (shown in a heat map).
B Co-stimulation of monocytes by GM3 species (16:0, 24:0, 24:1) plus synthetic TLR4 ligands LA506 (15 ng/ml), LA505 (150 ng/ml), or LA504 (150 ng/ml).
C, D Production of IL-6 (C) and TNF-a (D) in culture supernatant following co-stimulation of monocytes by GM3 species plus human HMGB1.
E Overexpression of hTLR4, hTLR4/hMD-2, and hTLR4 (P714H) /MD-2 in HEK293T cells, and co-stimulation by GM3 22:0 with LPS (5 ng/ml). TLR4 activation was
monitored by NF-jB luciferase reporter assay (termed “Relative Luc Activity” on y-axis).
F, G Co-stimulation of hTLR4/hMD-2 by GM3 species plus LPS (5 ng/ml) (F) and further addition of soluble human CD14 (1 lg/ml) (G).
H Stimulation of Mal-overexpressing HEK293T cells by GM3 species.
I Co-stimulation of hTLR4/hMD-2 by LPS (5 ng/ml) plus various mixtures of GM3 species.
J Regulation of hTLR4/hMD-2 by GM3 species balance (schematic).
Data information: Data shown are mean  SD (A–D and F-I, n = 3; E, n = 4) analyzed by Tukey’s multiple comparison test. *P < 0.05 and **P < 0.01 for comparisons
between indicated groups.
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Figure 6. GM3 species selectively modulate mouse TLR4/MD-2 signaling.
A Co-stimulation of RAW macrophages by GM3 species plus various TLR ligands: LPS (0.5, 1.0 ng/ml), bovine thymus HMGB1 (0.25 lg/ml), Pam3CSK4 (50 ng/ml), Poly
I:C (10 lg/ml), R848 (4 ng/ml), and CpG type B (20 nM). TNF-a production in culture supernatant was quantified by ELISA.
B Co-stimulation of RAW macrophages by low- and high-dose LPS (0, 5, 50 ng/ml) plus GM3 22:0 (5 lM). Time course of TNF-a production in culture supernatant was
quantified by ELISA.
C Co-stimulation of BMDMs from C3H/HeN or C3H/HeJ mice by GM3 species plus LPS (0.5 ng/ml), and TNF-a production in culture supernatant.
D Co-stimulation of mTLR4/mMD-2-expressing HEK293T cells by GM3 species plus LPS (2.5 ng/ml), and further addition of soluble mouse CD14-Fc fusion protein
(1 lg/ml).
E, F Co-stimulation of BMDMs from C3H/HeN mice by LPS plus GM3 species and complex ganglioside species (E; 2.5, 5.0, 10 lM), or by LPS plus GM3 species and
precursor GSL species (F; 2.5, 5.0, 10 lM) (shown in heat maps).
G Structure–bioactivity relationships of GM3 species with human or mouse TLR4.
Data information: Data shown are mean  SD (A and B, n = 3; C, E, and F, n = 4; D, n = 6) analyzed by Tukey’s multiple comparison test (A, C, and D) or two-tailed
unpaired t-test (B). *P < 0.05 and **P < 0.01 for comparison with stimulation by TLR ligand without GM3 species.
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partially reduced hTLR4 activation by LPS single stimulation
(Fig 8C). R322, which recognizes a heptulose-phosphate group on
LPS oligosaccharide region (Park et al, 2009), contributed weakly to
GM3-mediated TLR4 activation (Fig 8C). Mutations of R264A,
K341A, and K362A in combination effectively suppressed GM3-
mediated TLR4 activation (Fig 8D). On the other hand, nickel ion,
an allosteric TLR4 ligand (Schmidt et al, 2010), did not display
synergistic activation with GM3 22:0 (Appendix Fig S4). We also
confirmed that R264A, K341A, and K362A had no effect on nickel-
mediated hTLR4 activation. These findings indicate that R264,
K341, and K362 are required for hTLR4 activation by both LPS and
GM3 species and facilitate their synergistic activation, whereas
nickel ion does not synergize with GM3 species because its activity
is independent of these amino acids.
To clarify MD-2-dependent recognition of GM3 acyl-chain struc-
ture, we compared inhibitory effects of GM3 16:0 on mTLR4/mMD-
2, hTLR4/hMD-2, and mTLR4/hMD-2, a domain-swapped complex
comprised of mouse TLR4 and human MD-2. mTLR4/mMD-2 acti-
vation was not affected by 16:0 at physiological concentration
(Fig 8E), whereas mTLR4/hMD-2 activation and hTLR4/hMD-2
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Figure 7. a-hydroxy VLCFA-GM3 species in adipose tissue showed increased abundance in obesity.
A GM3 molecular species of 6-week-old control C57/BL6 mice and ob/ob mice were analyzed, respectively, by LC-MS/MS (n = 3).
B GM3 molecular species of normal diet (ND) and high-fat diet (HFD) C57/BL6 mice were analyzed by LC-MS/MS (n = 4).
C TLC analysis of acidic GSL fraction (equivalent to 0.1 mg protein) from epididymal fat pads of C3H/HeN (A) and C3H/HeJ mice (B) on ND or HFD for 8 weeks.
D GM3 molecular species of C3H/HeN mice (ND, HFD) and C3H/HeJ mice (ND, HFD) were analyzed by LC-MS/MS (n = 4).
E Comparison of increased GM3 species in human serum and mouse adipose tissue.
F Feedback loop mediated by TLR4 and GM3 species, promoting disease progression (schematic).
Data information: Data shown are mean  SD analyzed by two-tailed unpaired t-test (A, B) or by Tukey’s multiple comparison test (D). *P < 0.05 and **P < 0.01 for
comparisons between indicated groups.
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activation were strongly inhibited by 16:0 (Fig 8F and G). Thus,
MD-2 evidently provides a basis for selectivity for GM3 species.
To investigate activation state of TLR4/MD-2 complex induced
by GM3, we performed chemical cross-linking and SDS–PAGE anal-
ysis of recombinant mTLR4 extracellular domain/mMD-2 complex.
Addition of LPS, GM3 18:0, and chemical cross-linker induced large
mobility shift of mTLR4/mMD-2 complex and observed molecular
weights indicate the presence of dimers and higher-order oligomers
(Fig 8H). Previous reports indicate that LPS-mediated signal trans-
duction is initiated by dimerization of TLR4/MD-2 unit (Akashi
et al, 2001; Saitoh et al, 2004; Kobayashi et al, 2006). Clustering of
TLR4 was observed by fluorescent and electron microscopy after
LPS stimulation (Visintin et al, 2003; Triantafilou et al, 2004; Latty
et al, 2018), and the signaling was mediated by a left-handed helical
oligomer of downstream adaptors consisting death domains (Lin
et al, 2010); i.e., receptor oligomerization may provoke further
downstream signaling. These previous and current findings, taken
together, suggest that GM3 species act as TLR4-selective endoge-
nous modulators to induce receptor dimerization/ oligomerization,
and consequently enhance signal transduction leading to chronic
inflammation in metabolic disorders.
Molecular docking approach implicates different binding modes
of GM3 species modulating TLR4 activation
To figure out how GM3 species enhance and suppress TLR4 activa-
tion depending on the acyl-chain structure, we performed a ligand-
macromolecular docking study on hTLR4/hMD-2 complex. Binding
modes of VLCFA-GM3 (24:0) and LCFA-GM3 (16:0) were sought on
the molecular surface around the hydrophobic pocket of hMD-2 and
the basic residues of hTLR4. Docking models of hTLR4/hMD-2/
GM3 (24:0 or 16:0) complex are shown in Fig 9A and B. Similarly
to LPS and lipid IVa, both GM3 24:0 and 16:0 bound the hydropho-
bic pocket of hMD-2 via the fatty acid and the sphingoid base
(Fig 9C–E). The binding model of GM3 24:0 overlapped closely to
Ra-LPS in the crystal structure of reference, and the saccharide
chain of GM3 24:0 was surrounded by basic residues of TLR4
(Figs 9C and EV5A–C). The basic residues of TLR4 (K341, K362,
and R322), that interact with the saccharide chain of LPS and show
conformational changes upon TLR4 activation (Park et al, 2009;
Ohto et al, 2012b), were closely associated with the saccharide
chain of GM3 24:0. However, R264, a key residue recognizing 40-
phosphate of LPS and triggering TLR4 activation (Park et al, 2009),
was far from the saccharide chain of GM3 24:0. These results imply
the underlying mechanism of VLCFA-GM3 capability to enhance
TLR4 signaling without triggering activation by itself. Since syner-
gistic activation by VLCFA-GM3 was mainly observed in the pres-
ence of low-dose LPS or weak TLR4 ligands, VLCFA-GM3 may act
as an endogenous LPS mimic without intrinsic activity, which could
sensitize TLR4 signaling by decreasing the ligand concentration
required for TLR4 activation and increasing dimer/ oligomer forma-
tion (Fig 9F).
Next, binding model of GM3 16:0 was compared to lipid IVa in
complex with hMD-2 (Figs 9E and EV5D–F). Lipid IVa shows dif-
ferent binding mode in comparison with LPS, with reverse orienta-
tion of 40-phosphate and acyl chains, which may inhibit dimer
formation of hTLR4/hMD-2 by presenting hydrophilic groups (phos-
phate and glucosamine) to the lipophilic dimer interface (Park et al,
2009; Ohto et al, 2012a; Fig 9C and E). Similarly, GM3 16:0 showed
opposite binding mode to GM3 24:0, with reverse orientation of the
saccharide chain and the acyl chain (Fig 9D), which may interfere
and reduce TLR4 activation through presentation of the saccharide
chain to the dimer interface (Figs 9E and EV5D–F). On the other
hand, lipid IVa and lipid A (LPS-core structure) are known to show
same binding orientations on mTLR4/mMD-2 (Ohto et al, 2012a).
Binding model of GM3 16:0 on mTLR4/mMD-2 showed almost the
same orientation compared with GM3 24:0 (Appendix Fig S5A–C).
These comparative analyses implicate the mechanism by which
GM3 species can enhance and reduce TLR4 activation in an acyl-
chain-dependent manner.
Discussion
TLR4 signaling plays crucial roles in pathogenesis of obesity and
metabolic disorders. This study demonstrated that human TLR4/
MD-2 received positive regulation by VLCFA-/a-hydroxy VLCFA-
GM3 and negative regulation by LCFA-/unsaturated VLCFA-GM3 in
the presence of LPS and HMGB1. LCFA-GM3 species such as 16:0
consistently inhibited TLR4 activation even in the presence of
VLCFA-GM3 species 22:0 or 24:0; 18:0; and 20:0 (Fig 5I). These
findings indicate that GM3 species function as a rheostat for TLR4
signaling (Fig 5J). Increases in VLCFA-/a-hydroxy VLCFA-GM3
species, and decreases in LCFA-GM3 species, were involved in
pathogenesis of metabolic disorders via chronic inflammatory
processes. Computational approaches revealed that elongation, a-
hydroxylation, and desaturation of fatty-acid structures of GM3
were related to signatures of disease progression. a-hydroxy VLCFA-
GM3 species were also increased in adipose tissue of obese mice.
The increase in a-hydroxy VLCFA-GM3 was attenuated by TLR4
mutation, implying a feedback loop from TLR4 activation to GM3
production, analogous to that for free fatty acids (Suganami et al,
2007). GM3 induced dimerization/ oligomerization of TLR4/MD-2,
and MD-2 was involved in recognition of the fatty-acid structure of
GM3. These findings suggest that GM3 plays an important role in
TLR4 signaling, and the increase in VLCFA-GM3 species, showing
the strongest synergistic TLR4 activation, is a risk factor for TLR4-
mediated disease progression.
Measurement of serum GM3 species will potentially allow evalu-
ation of hidden risks of TLR4-signaling-related inflammatory
diseases (e.g., inflammatory bowel disease, chronic kidney disease,
rheumatoid arthritis, cancer metastasis) via LPS and endogenous
ligands such as HMGB1, S100A8/9 (Mrp8/14), and SAA3 (Vogl
et al, 2007; Hiratsuka et al, 2008; Harris et al, 2012). Over 20 GM3
species, in addition to the ten major species examined in this study,
are present in human serum (Veillon et al, 2015). Moreover, there
is increasing evidence for important roles of GSLs in innate immune
responses and chronic inflammation (Kondo et al, 2013; Nakayama
et al, 2016; Nagata et al, 2017; Nitta et al, 2019). Expression pattern
analysis utilizing artificial intelligence will allow us to deal effec-
tively with the complexity and variety of GM3 and other GSL
species, and to further elucidate the relationships between particular
species and inflammatory diseases.
The detailed mechanism whereby GM3 species are secreted and
presented to TLR4/MD-2 complex is currently under study. It is
supposed that GM3 is secreted as part of a lipoprotein complex
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(Senn et al, 1989; Veillon et al, 2015) allowing circulation from the
liver to most body tissues, including adipose tissue. TLR4 has been
shown to mediate innate immune responses by LDL cholesterol
(Stewart et al, 2010). Ceramide 24:0 is preferentially incorporated
into LDL cholesterol (Boon et al, 2013). The present study shows
that levels of VLCFA-GM3 and non-HDL cholesterol increase
together, whereas levels of LCFA-GM3 and HDL cholesterol
decrease together, indicating species-selective incorporation into
lipoproteins. However, other secretion pathways, such as exosomes
and microvesicles (Skotland et al, 2017), may also be involved.
Furthermore, a-hydroxylation, mediated by enzymes such as fatty
acid-2 hydroxylase (FA2H), may contribute to secretion of GM3
species via reducing hydrophobicity and affecting lipid diffusion
(Hama, 2010).
In regard to activation mechanisms, our results displayed that
CD14 and MD-2 facilitate GM3 to modulate TLR4 signaling. It is
possible that CD14, MD-2, and LPS-binding protein take up serum
GM3 species and transport them to TLR4, as reported for LPS (Ryu
et al, 2017). As shown in docking study, VLCFA-GM3 and LCFA-
GM3 may interact with TLR4/MD-2 by utilizing different interaction
modes to promote or disrupt dimerization, similarly to lipid A/IVa
species and eritoran (a strong antagonist in lipid IVa analogs)
(Mullarkey et al, 2003; Kim et al, 2007; Ohto et al, 2007, 2012a;
Appendix Fig S3). In particular, molecular features of LCFA-GM3
and unsaturated VLCFA-GM3 resemble those of eritoran: (i) short
aliphatic-chain length (C10) in comparison with agonistic lipid A
species (C14) and (ii) desaturation (C18:1, x-7) making a 180-
degree turn of the acyl chain in the hydrophobic pocket of MD-2
(Kim et al, 2007). Mimetic compounds based on lipid A/IVa precur-
sors (diacyl monosaccharide species), carrying less number of fatty
acids, show antagonistic effect (Facchini et al, 2018). Thus, less
fatty-acid number, shorter acyl-chain length, and desaturation may
cooperatively contribute to antagonistic activity by affecting interac-
tion mode. Our findings suggest that GM3 species modulate TLR4
activation by utilizing molecular mechanisms closely related to lipid
A/ IVa. Formation of two ligand-binding pockets on the dimeriza-
tion interface between two TLR4/MD-2 units has been suggested by
crystallographic analyses (Park et al, 2009; Ohto et al, 2012a).
Reported binding study of TLR4/MD-2 with lipid A suggests that the
maximal binding of the agonistic E. coli lipid A was approximately
half-fold lower than that of the antagonistic lipid IVa (Akashi et al,
2001; Saitoh et al, 2004); i.e., under physiological conditions, one
ligand pocket is occupied by agonist (e.g., LPS) while the other is
vacant or occupied by unknown intrinsic ligands. It may allow GM3
species to modulate dimerization efficiency via the second pocket
(Fig 9F and G). Future studies are expected to reveal structures of
oligomeric TLR4/MD-2 signalosomes complexed with GM3 species.
Additionally, it is known that the dimerization and internalization
of mTLR4/MD-2 upon acute stimulation by LPS can be analyzed by
flow cytometry (Akashi et al, 2003; Zanoni et al, 2011; Tan et al,
2015), which might enable to detect GM3-mediated receptor dynam-
ics directly on the plasma membrane of living cells.
Biosynthesis of the various GM3 species may depend on several
enzymes: fatty-acid elongases (Elovls), acyl-CoA desaturases, cera-
mide synthases (CerSs), and GM3S. Blocking of 16:0-to-18:0 fatty-
acid elongation in mice by Elovl6 knockout was found to inhibit
progression of metabolic disorders through alterations of fatty-acid
structures, i.e., increased 16:0 and decreased 18:0-to-24:0 levels
(Matsuzaka et al, 2007). Elovl6 deficiency therefore may attenuate
increase in VLCFA-GM3 species, and achieve homeostatic balance
of acyl-chain structures. On the other hand, increase in LCFA-Cer
(16:0) and decreases in VLCFA-Cer (22:0, 24:0) in obese subjects,
resulting from imbalance of CerS2/6 expression and inhibition of
b-oxidation, were reported to correlate to progression of metabolic
disorders (Raichur et al, 2014; Turpin et al, 2014). Our results
imply that such imbalances in Cer species might be involved in
decreased production of LCFA-GM3 and increased production of
VLCFA-GM3 in metabolic disorders. Fatty-acid desaturation was
shown to occur in the resolution phase of innate immune
response, and to reduce inflammation (Oishi et al, 2017); however,
the direct mechanism whereby x-9 mono-unsaturated VLCFA
attenuates chronic inflammation is not completely understood.
Increased levels of unsaturated GM3 species in severe metabolic
disorders may result from desaturation mechanisms after the acti-
vation phase. Both elongase and desaturase genes are regulated by
SREBP-1, a key transcription factor in lipid signaling whose activa-
tion occurs in parallel with that of NF-jB (Matsuzaka et al, 2007;
Oishi et al, 2017). We previously reported that proinflammatory
cytokines TNF-a and IL-1b induce GM3S expression and GM3
production in adipocytes (Tagami et al, 2002; Nagafuku et al,
2015). In the present study, TLR4 deficiency reduced production of
a-hydroxy VLCFA-GM3 (Fig 7D), suggesting the involvement of
TLR4 signaling in GM3 production. These previous and current
findings indicate that fatty-acid structures and total expression
level of GM3 species are controlled by complex, coordinated mech-
anisms regulated by innate immune signaling, lipid signaling, and
other cellular responses.
Moreover, it should be clarified directly in adipose tissue that
GM3 species could mediate the adipocyte–macrophage communica-
tion in the future study. It would be important to specify the GM3
and other ganglioside species expressed in a specific type of cells,
such as macrophages, pre-adipocytes, and differentiated adipocytes,
that are mixed in adipose tissue. While pre-adipocytes/adipocytes
predominantly express GM3, it is considered that human monocytes
and mouse macrophages express GM3 and GM1/GD1a, respectively
(Yohe et al, 2001; Tanabe et al, 2009). However, it remains unclear
how ganglioside species and their acyl-chain structures are different
in a cell-type-specific manner in the intact adipose tissue. To char-
acterize miscellaneous cells in adipose tissue, in vitro enzymatic
digestion/fractionation and antibody-based cell sorting are
performed generally. On the other hand, our previous report
suggested that GM3 expression in adipocytes was regulated by the
co-presence of the resident macrophages in adipose tissue (Naga-
fuku et al, 2015). It has been also known that the activation of GM3
synthase in monocyte/macrophages was easily occurred during
culturing in vitro (Gracheva et al, 2007). Therefore, the specific
method such as the imaging mass spectrometry for GM3 species
should be established in order to analyze GM3 species directly in
the intact adipose tissues without in vitro cell manipulation (Sugi-
moto et al, 2016).
In regard to potential therapeutic approaches, treatment with
supplemental LCFA-GM3 16:0 may inhibit systemic and local
production of TNF-a, IL-6, and IL-12/23 via TLR4, and in part via
TLR2, driven by LPS and HMGB1. On the other hand, VLCFA-GM3
24:0 could act as a booster for immunological adjuvants such as
monophosphoryl lipid A species (LA505, LA504) and other synthetic
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TLR4 ligands (Wang et al, 2016; Chan et al, 2017; Okamoto et al,
2017). Utilization of naturally occurring GM3 species may prevent
production of autoantibodies (Bowes et al, 2002).
In conclusion, our findings would help clarify the pathophysio-
logical roles of serum/ adipose GM3 species in TLR4 signaling, and
the complex interplay between glycosphingolipid metabolism and
innate immune signaling in metabolic disorders.
Materials and Methods
Ceramide, GSLs, and complex gangliosides
Ceramide species (16:0, 24:0, 24:1) and GlcCer species (16:0, 24:1)
were from Avanti Polar Lipids (Alabaster, AL, USA). GlcCer (24:0),
LacCer (16:0, 24:0, 24:1), and GM3 (16:0, 18:0, 20:0, 22:0, 24:0,
h24:0, 24:1) and GM1 (18:0) were synthesized as described previ-
ously (Murase et al, 1989; Mauri et al, 1999). GM2 (from brain of
Tay-Sachs disease patient) was from Matreya (State College, PA,
USA). Brain GD1a, GD1b, and GT1b were from Sigma-Aldrich (St.
Louis, MO, USA). Brain GQ1b was from AdipoGen Life Sciences
(San Diego, CA, USA). Milk GD3 was from Nagara Science Co.
(Gifu, Japan). Ceramides, GlcCer, and LacCer species were
dissolved at 1 mM in warmed DMSO. Gangliosides were dissolved
at 0.5 mM concentration in warmed low-glucose DMEM (Nacalai
Tesque; Kyoto, Japan). Stock solutions were stored at 30°C and
diluted with low-glucose DMEM to 100 lM concentration prior to
experiments.
TLR ligands and recombinant proteins
Toll-like receptors ligands and recombinant proteins were
purchased from the following vendors: LPS from E. coli O111:B4
(Sigma-Aldrich); human recombinant HMGB1, soluble form human
CD14 (BioLegend; San Diego); bovine thymus HMGB1 (Chondrex;
Redmond, WA, USA); soluble form mouse CD14-Fc fusion (Sino
Biological, Inc.; Beijing, China); Pam3CSK4 and MALP-2 (Novus
Biologicals; Littleton, CO, USA); and Poly I:C, R848, Flagellin from
Salmonella typhimurium, and CpG (ODN 1826) (Enzo Life Sciences;
Farmingdale, NY, USA). TLR ligands other than R848 were reconsti-
tuted in endotoxin-free water (Nacalai Tesque). R848 was reconsti-
tuted in ethanol (Fujifilm Wako; Osaka, Japan). Lipid A and
derivatives were previously synthesized (Imoto et al, 1985, 1987;
Liu et al, 1999).
Vector construction
Vector carrying mouse MD-2 and TLR4 cDNA (pDUO-mMD2/
TLR4) was from InvivoGen (San Diego). cDNA fragments, fused
with a KpnI site and one Kozak sequence (ACC) at 50-end and
SalI site at 30-end, were amplified by PCR (KOD-Plus-Neo;
Toyobo) and inserted separately into pCDNA3 at KpnI and XhoI
sites (Invitrogen). A set of vectors for dual luciferase assay, NF-
jB reporter gene (pGL3-ELAM; a firefly luciferase gene controlled
by NF-jB-dependent promoter of ELAM-1), control reporter gene
(pRL-TK; a Renilla luciferase gene controlled by constitutive active
promoter of thymidine kinase), and pCDNA3 vectors carrying
human MD-2 and TLR4 cDNA were previously described (Muta &
Takeshige, 2001; Fujimoto et al, 2004). Reporter vectors for AP-1
and ISRE were purchased (Promega; Australia). Site-directed
mutagenesis was performed according to the manufacturer’s
protocol of QuikChange (Agilent; Santa Clara, CA, USA) with
minor modifications.
Purification and stimulation of human monocytes
Heparinized fresh human peripheral blood was diluted to 2× volume
with cold (4°C) endotoxin-free PBS (Nacalai Tesque) containing
1 lg/ml polymyxin B (Sigma-Aldrich). Diluted blood was overlaid
on cold (4°C) lymphocyte separation solution (Nacalai Tesque)
containing 1 lg/ml polymyxin B and centrifuged at 800 g for
25 min at 4°C. Peripheral blood mononuclear cell (PBMC) fraction
was collected and diluted to 2× volume of wash solution (PBS, 1%
heat-inactivated FCS (Biosera), 5 mM EDTA, pH 7.5 (Nacalai
Tesque), 1 lg/ml polymyxin B). PBMCs were separated by centrifu-
gation at 600 g for 10 min at 4°C, washed twice, resuspended in
750 ll wash solution and incubated with 120 ll anti-human CD14
magnetic particles (BD Biosciences) for 30 min at room tempera-
ture. CD14-positive cells (monocytes) were separated by magnetic
field and washed 3× with wash solution. Purified cells were resus-
pended in cold low-glucose DMEM with 0.75% FCS, left on ice for
45 min, counted, diluted to 2.0 × 105 cells/ml with culture medium
(low-glucose DMEM, 0.75% FCS, 40 ng/ml recombinant human
granulocyte-macrophage colony-stimulating factor (GM-CSF)
(BioLegend), and cultured in 96-well plates (100 ll/well) overnight
at 37°C under 5% CO2 atmosphere.
Differentiation of mouse bone marrow-derived macrophages
(BMDMs)
Femoral and tibial bone marrows of 12- to 16-week-old nondiabetic
C3H/HeN mice (Japan SLC Inc.) were collected in 1% FCS-supple-
mented low-glucose DMEM, and erythrocytes were lysed in RBC
lysis buffer. Bone marrow cells were washed in 1% FCS DMEM and
cultured 5–7 days in 10% FCS DMEM supplemented with 40 ng/ml
recombinant human macrophage colony-stimulating factor (M-CSF)
(BioLegend). Non-adhesive cells were washed out with PBS. Dif-
ferentiated macrophages were collected by scraping in ice-cold PBS
with 1% FCS/ 5 mM EDTA, washed, counted, diluted to
2.0 × 105 cells/ml in 1% FCS DMEM, and cultured in 96-well plates
overnight at 37°C under 5% CO2 atmosphere.
Cell culture and transfection
HEK293T cells (RIKEN BioResource Center; Wako, Japan) were
maintained in 10% FCS low-glucose DMEM at 37°C under 5% CO2
atmosphere. Prior to transfection, cells were diluted to 2.0 × 105/ml
in 1% FCS DMEM and cultured in 96-well plates overnight. Cells in
each well were transfected with reporter vectors (40 ng pGL3-
ELAM, 20 ng pRL-TK) and expression vectors (hTLR4/hMD-2, 20 ng
pCDNA3-hMD-2 and 40 ng pCDNA3-hTLR4; mTLR4/mMD-2, 20 ng
pCDNA3-mMD-2 and 1 ng pCDNA3-mTLR4; mTLR4/hMD-2, 20 ng
pCDNA3-hMD-2 and 1 ng pCDNA3-mTLR4; and hMal, 0.1 or 0.5 ng
pCDNA3-hMal), complexed with 0.5 ll Lipofectamine LTX and
0.25 ll Plus reagent in 20 ll Opti-MEM (Invitrogen), and subjected
to stimuli 24 h after transfection.
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Cell stimulation, ELISA, and luciferase assay
Cells were primed for 30 min with various sphingolipids and then
stimulated with TLR ligands. After 18-h culture, media were collected
and subjected to ELISA. ELISA kits for human IL-6, human TNF-a,
human IL12/23 p40, and mouse TNF-a were from BioLegend. Firefly
and Renilla luciferase activities were measured using Dual-Glo Luci-
ferase Assay System (Promega; Australia) on a microplate reader
(model Infinite M1000 PRO, Tecan Group; Ma¨nnedorf, Switzerland).
TLC and LC-MS/MS analysis of GM3 species
Total lipids in lyophilized human serum were extracted with chloro-
form/ methanol (2:1 and 1:1, v/v) and separated into acidic and
neutral fractions on DEAE-Sephadex A-25 anion-exchange columns
(GE Healthcare Life Sciences; Nitta et al, 2019). Acidic fraction was
de-esterified by mild alkaline hydrolysis for phospholipids, followed
by desalting using a Sep-Pak C18 cartridge (Waters; Milford, MA,
USA). Acidic GSLs in mouse adipose tissues were separated by
Ladisch’s partitioning method as previously described (Tagami et al,
2002). Acidic GSLs (respective protein equivalent 100 lg [mouse
adipose tissue] or respective volume equivalent 1 ml [human
serum]) were spotted on HPTLC plates, developed, respectively,
with chloroform/ methanol/ 0.2% CaCl2 (55:25:10, v/v/v) and chlo-
roform/ methanol/ water (60:25:4, v/v/v), and visualized by orci-
nol/ sulfuric acid staining. Acidic GSLs were also subjected to LC-
MS/MS analysis by running method as described previously (Veil-
lon et al, 2015; Go et al, 2017). 100 ng of the deuterated GM3
(d18:1-[13C]16:0) was added for internal standard. Relative abun-
dance of a particular GM3 species was expressed as peak area of
that species divided by total peak area. For comparison of GM3
species among different mouse groups, total abundance of GM3
species in control group was defined as 1, and the abundances of
each GM3 species in both control and fatty (e.g., HFD, ob/ob) group
were normalized and displayed as relative amounts.
Analysis of LC-MS/MS data of GM3 species in sera of
presymptomatic subjects and patients with metabolic disorders
LC-MS/MS data and clinical markers of human subjects were
obtained in previous study (Veillon et al, 2015), and relative abun-
dances of ten major GM3 species (fatty acid: 16:0, 18:0, 20:0, 22:0,
23:0, 24:0, h24:0, 22:1, 24:1, h24:1) with reference to their total (de-
fined as 1) were newly evaluated for each subject. Trends of each
species in terms of pathological phases and Spearman’s correlation
coefficient in relation to clinical markers of metabolic disorders and
chronic inflammation were analyzed. Self-organization map (SOM)
and Bayesian regularized neural-network (BRNN) analysis were
performed as described previously (Aoki et al, 2011).
Animal studies
Six-week-old male ob/ob and control background (C57/BL6) mice
were from CLEA Japan (Tokyo). Eight-week-old male C57/BL6,
C3H/HeN, and C3H/HeJ (TLR4 mutant; Poltorak et al, 1998) mice
(Japan SLC) were divided randomly into two groups. The control
group was fed normal diet (ND) (CE-2; CLEA Japan), while the HFD
group was fed high-fat diet (HFD) (D12492; Research Diet; New
Brunswick, NJ, USA) ad lib for 8 weeks (C3H/HeN, C3H/HeJ) or 10
weeks (C57/BL6). Epididymal fat pads and blood (from right ventri-
cle) were harvested from sacrificed animals, and non-fasting blood
glucose level was measured using Accu-Chek Aviva strips (Roche
DC; Japan).
Cross-linking and SDS–PAGE analysis
The recombinant mouse TLR4 (extracellular domain)/mMD-2
proteins were prepared as described previously (Ohto et al, 2012a).
Mouse TLR4/mMD-2 complex proteins (1.5 lg) were mixed with
GM3 18:0 (final 0.0071, 0.71, 71 lM) and incubated at room temper-
ature for 1 h. LPS (0.05 lg) was added to the complex and incubated
at 37°C for 1 h. Cross-linking was performed by incubation with
0.6 lmol DMP (dimethyl pimelimidate; Thermo Fisher Scientific) at
room temperature for 1 h. Cross-linked protein complex was
analyzed by SDS–PAGE (5–10% gradient gel) and silver-stained.
Ligand-macromolecular docking
Molecular editing and lowest-energy calculation of GM3 24:0 and
16:0 were performed on Avogadro molecular editing software (Han-
well et al, 2012), and their three-dimensional structures were
exported as PDB files. Ligand-macromolecular docking between
GM3 species and TLR4/MD-2 complex was performed on AutoDock
4.2 molecular docking software (Morris et al, 2009). Grid settings
for generating the binding surface on hTLR4/hMD-2 were below:
spacing, 0.431 A˚; grid points, 60, 80, and 80; center of grids, 25,
13, and 15 (on x-, y-, and z-axis). Grid settings for mTLR4/mMD-2
were below: spacing, 0.431 A˚; grid points, 80, 60, and 80; and
center of grids, 30, 16, and 17 (on x-, y-, and z-axis). Lamarckian
genetic algorithm was used for searching candidate binding modes,
and the binding mode with lowest energy was exploited from 100
calculation results. As a benchmark, rigid-rigid dockings of Ra-LPS
(conformer in 3FXI) vs. hTLR4/hMD-2 (3FXI, chains A and C) and
lipid A (conformer in 3VQ2) vs. mTLR4/mMD-2 (3VQ2, chains A
and C) were performed (Appendix Fig S5D and E). Same settings
and procedures for calculation were applied for searching rigid-rigid
binding modes of GM3 species on human and mouse TLR4/MD-2
complex. All molecular/ protein structures were visualized by
PyMOL software (DeLano Scientific).
Ethics and informed consents for human-subjected study
All participants gave their written informed consent prior to their
inclusion in the study. The experimental protocol was in agreement
with international norms and approved by the ethics committee of
the University of Tokyo and Tohoku Medical and Pharmaceutical
University.
Statistical analysis
Data were expressed as mean  SD and analyzed by two-tailed
unpaired t-test or Tukey’s multiple comparison (honesty significant
difference) test using Microsoft Excel (Microsoft) and StatPlus:Mac
Pro (AnalystSoft; Walnut, CA, USA). Differences between means
were considered significant for P < 0.05 (*), < 0.01 (**), or < 0.001
(***).
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Data availability
The mass spec data of the GM3 species in human serum are avail-
able at the database GlycoPOST (https://glycopost.glycosmos.org).
The accession number is GPST000057.
Expanded View for this article is available online.
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